The Science of Gonorrhoea

The gonococcus is a Gram-negative diplococcus — pairs of kidney-shaped cells enclosed in a shared outer membrane. Its outer surface is covered in several structures that are critical to its virulence and its ability to evade immunity:

• Type IV pili: Long, flexible filaments that extend from the bacterial surface. They mediate initial attachment to host epithelial cells, allow the bacterium to move (twitching motility), and facilitate DNA uptake. Pili are also a major target of the immune system — and gonorrhoea evades this by constantly varying their surface proteins.
• Opacity (Opa) proteins: Outer membrane proteins that mediate tighter adhesion and entry into host cells. Different Opa variants interact with different host cell receptors, and gonorrhoea switches between them using a mechanism called phase variation — turning individual protein expression on or off by slipping repetitive DNA sequences in or out of the reading frame.
• Lipooligosaccharide (LOS): The outer membrane equivalent of LPS (endotoxin) in other Gram-negative bacteria. It triggers the inflammatory cascade responsible for many of gonorrhoea's symptoms. Gonorrhoea also coats its LOS with sialic acid — a molecule found on human cells — effectively camouflaging itself from complement-mediated killing.

One of the most striking features of N. gonorrhoeae is its ability to continuously alter the surface proteins that the immune system recognises as foreign. This is called antigenic variation, and in gonorrhoea it is achieved with exceptional sophistication.

The bacterial chromosome contains multiple silent partial copies of the pilin gene (pilS loci) alongside the expressed copy (pilE). Through a process of gene conversion — essentially intrachromosomal recombination — different silent sequences are copied into the expression locus, generating new pilin variants. A single gonorrhoea cell can produce millions of antigenically distinct variants during an infection.

This is why the immune system struggles to mount lasting protective immunity against gonorrhoea. Unlike most pathogens, a previous infection does not protect against reinfection — the bacterium the immune system learned to recognise may bear no surface resemblance to the new infecting strain.

Gonorrhoea is classified by the WHO as a priority pathogen for antimicrobial resistance research — meaning strains capable of causing untreatable infections have already been identified. The trajectory of resistance follows a predictable but alarming pattern:

• Penicillin resistance: Emerged in the 1970s–80s via two mechanisms: penicillinase-producing strains (acquired a plasmid encoding beta-lactamase) and chromosomally-mediated resistance through mutations in penicillin-binding proteins and reduced outer membrane permeability.
• Fluoroquinolone resistance: Widespread by the 2000s. Mutations in the genes encoding the DNA gyrase and topoisomerase IV enzymes (gyrA, parC) — both targets of fluoroquinolones — are now near-universal. Fluoroquinolones are no longer recommended for gonorrhoea anywhere in the world.
• Cephalosporin resistance: Ceftriaxone (an injectable third-generation cephalosporin) is now the last reliably effective first-line monotherapy. Resistance is driven by mosaic penA gene sequences — created by recombination with DNA from commensal Neisseria species in the throat — alongside mutations in mtrR and porB. Fully resistant strains (MIC ≥ 0.125 mg/L) have been documented in multiple countries.

N. gonorrhoeae is a naturally transformable bacterium — it can take up DNA from its environment and integrate it into its chromosome. This accelerates resistance evolution because genes conferring resistance in one strain can be shared with others through horizontal gene transfer, even across species within the Neisseria genus.

The anatomical site of infection matters significantly for gonorrhoea biology. Pharyngeal (throat) gonorrhoea is often asymptomatic and harder to clear — but it is also epidemiologically important because the throat is a mixing vessel where gonorrhoea can exchange genetic material with commensal Neisseria species (such as N. meningitidis and N. lactamica). This is the mechanism by which mosaic resistance genes are assembled. Pharyngeal infections are a key driver of the resistance crisis. Rectal gonorrhoea similarly tends to be asymptomatic in many patients, making untreated carriage — and onward transmission — highly likely without routine screening.

With ceftriaxone resistance emerging, the pipeline of novel anti-gonococcal agents is critically important. Current candidates include:

• Zoliflodacin: A first-in-class spiropyrimidinetrione antibiotic that inhibits DNA gyrase via a completely different binding site to fluoroquinolones. Phase 3 clinical trial data published in 2024 showed non-inferiority to ceftriaxone for uncomplicated gonorrhoea. Crucially, it is active against ceftriaxone-resistant strains.
• Gepotidacin: Another novel gyrase inhibitor with a distinct mechanism. Demonstrated efficacy in phase 3 trials for gonorrhoea and urogenital infections.
• Vaccine development: Historically considered difficult due to antigenic variation. However, observational data showed that the MeNZB meningococcal B vaccine offered partial cross-protection against gonorrhoea (around 30%). This has accelerated research into a dedicated gonococcal vaccine using conserved outer membrane proteins as antigens.